Haleos Labs (NSE:HALEOSLABS) EBIT: ₹316 Mil (TTM As of Mar. 2026)


NSE:HALEOSLABS Haleos Labs Ltd NSE:HALEOSLABS
72 GF Score
Price ₹1,612.30
GF Value ₹1,123.78
Valuation Significantly Overvalued
! 10 Warning Signs
View Full Analysis

What is Haleos Labs EBIT?

Haleos Labs NSE:HALEOSLABS -0.50% 72 EBIT is ₹316 Mil as of Mar. 2026. GuruFocus rates NSE:HALEOSLABS with a GF Score™ of 72/100 and a GF Value™ of ₹1,123.78 (Significantly Overvalued). The stock has 10 warning signs investors should review.

Haleos Labs's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was ₹23 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹316 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Haleos Labs's annualized ROC % for the quarter that ended in Mar. 2026 was 0.12%. Haleos Labs's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 2.72%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Haleos Labs's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 5.27%.


Haleos Labs  (NSE:HALEOSLABS) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Haleos Labs's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=12.44 * ( 1 - 62.02% )/( (0 + 3906.33)/ 1 )
=4.724712/3906.33
=0.12 %

where

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=4544.084 - 614.061 - ( 23.693 - max(0, 1562.775 - 1631.055+23.693))
=3906.33

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Haleos Labs's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=93.036/( ( (0 + max(0, 0)) + (2781.13 + max(642.292, 0)) )/ 1 )
=93.036/( ( 0 + 3423.422 )/ 1 )
=93.036/3423.422
=2.72 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0) - (0 + 0 + 0)
=0

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(613.393 + 798.242 + 195.727) - (614.061 + 0 + 351.009)
=642.292

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Haleos Labs's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=316.415/6009.037
=5.27 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Haleos Labs EBIT Related Terms


Haleos Labs EBIT Historical Data

* Premium members only.

The historical data trend for Haleos Labs's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Haleos Labs EBIT Chart

Haleos Labs Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 384.31 230.17 198.00 349.02 316.42

Haleos Labs Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 59.63 88.86 101.08 103.22 23.26

NSE:HALEOSLABS vs VRTX, REGN, ALNY: EBIT Comparison

For the Biotechnology subindustry, Haleos Labs's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Haleos Labs EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Haleos Labs's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Haleos Labs's EV-to-EBIT falls into.


NSE:HALEOSLABS
72GF Score
Haleos Labs Ltd NSE:HALEOSLABS
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Haleos Labs EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹316 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of ₹316 Mil mean?
Haleos Labs (NSE:HALEOSLABS) has a EBIT of ₹316 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Haleos Labs.
Is Haleos Labs' EBIT too high?
Haleos Labs' current EBIT is ₹316 Mil. Overall, Haleos Labs has a GF Score™ of 72/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Haleos Labs' EBIT compare to VRTX and REGN?
Haleos Labs' EBIT of ₹316 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Haleos Labs. Haleos Labs's current EBIT is ₹316 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Haleos Labs stock overvalued right now?
Based on GuruFocus' analysis, Haleos Labs (NSE:HALEOSLABS) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹1,123.78, compared to a current price of ₹1,612.30 — trading 43.5% above its estimated fair value. The current EBIT is ₹316 Mil. Haleos Labs' overall GF Score™ is 72/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Haleos Labs (NSE:HALEOSLABS), the current EBIT is ₹316 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Haleos Labs (NSE:HALEOSLABS) Overvalued in 2026?

Based on GuruFocus' analysis, Haleos Labs stock appears to be overvalued. The current stock price of ₹1,612.30 is trading 43.5% above its estimated GF Value™ of ₹1,123.78. GuruFocus considers Haleos Labs to be Significantly Overvalued.

Key valuation signals for NSE:HALEOSLABS:

  • EBIT: ₹316 Mil
  • GF Value™: ₹1,123.78 vs. price of ₹1,612.30 (43.5% above fair value)
  • GF Score™: 72/100 with 10 warning signs

No single metric tells the full story. See the NSE:HALEOSLABS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Haleos Labs Business Description

Other Exchanges 540679:India
Address Road Number 71, Plot Number 19 - III, Opposite Bharatiya Vidya Bhavan Public School, Jubilee Hills, Hyderabad, TG, IND, 500096
Haleos Labs Ltd is engaged in the Business of manufacturing Active Pharmaceutical Ingredients (APIs) and its intermediates and sells its products in India as well as exports. The group sells its products in India and also exports it to other countries. Some of its API products are used in therapy as an Antiulcer, Antifungal, Anti Obesity, Anesthesia, and others. The company has manufacturing facilities at Kazipally and Jeedimetla and its Research and Development center at Sanatnagar in Hyderabad.
72GF Score

Get the complete analysis for NSE:HALEOSLABS

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,612.30
Price
₹1,123.78
GF Value